A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
作者信息
Pleyer Christopher, Tian Xin, Rampertaap Shakuntala, Mu Rui, Soto Susan, Superata Jeanine, Gaglione Erika, Sun Clare, Lotter Jennifer, Stetler-Stevenson Maryalice, Yuan Constance M, Maric Irina, Pittaluga Stefania, Rosenzweig Sergio, Fleisher Thomas, Wiestner Adrian, Ahn Inhye E
机构信息
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
出版信息
Am J Hematol. 2020 Nov;95(11):E310-E313. doi: 10.1002/ajh.25968. Epub 2020 Sep 8.
Abstract
摘要
相似文献
1
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.一项关于依鲁替尼和短疗程氟达拉滨用于既往未治疗的慢性淋巴细胞白血病患者的II期研究。
Am J Hematol. 2020 Nov;95(11):E310-E313. doi: 10.1002/ajh.25968. Epub 2020 Sep 8.
2
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.一线维奈托克联合治疗与化疗免疫治疗在适合的慢性淋巴细胞白血病患者中的比较（GAIA/CLL13）：多中心、开放标签、随机、3 期临床试验的 4 年随访结果。
Lancet Oncol. 2024 Jun;25(6):744-759. doi: 10.1016/S1470-2045(24)00196-7.
3
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.依鲁替尼联合氟达拉滨、环磷酰胺和利妥昔单抗作为年轻慢性淋巴细胞白血病患者的初始治疗：一项单臂、多中心、2期试验。
Lancet Haematol. 2019 Aug;6(8):e419-e428. doi: 10.1016/S2352-3026(19)30104-8. Epub 2019 Jun 14.
4
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.伊布替尼联合利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的比较
N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.
5
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.伊布替尼、氟达拉滨、环磷酰胺和奥滨尤珠单抗（iFCG）方案治疗伴有IGHV 突变且无 TP53 异常的慢性淋巴细胞白血病（CLL）。
Leukemia. 2021 Dec;35(12):3421-3429. doi: 10.1038/s41375-021-01280-8. Epub 2021 May 18.
6
Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada.加拿大不列颠哥伦比亚省接受慢性淋巴细胞白血病治疗的患者，其年龄和治疗机构类型对结局的影响。
Leuk Res. 2021 Apr;103:106538. doi: 10.1016/j.leukres.2021.106538. Epub 2021 Feb 18.
7
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.CLL 中采用固定时间、可衡量的残留病灶指导治疗方法：来自 2 期 ICLL-07 FILO 试验的随访数据。
Blood. 2021 Feb 25;137(8):1019-1023. doi: 10.1182/blood.2020008164.
8
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.伊布替尼作为慢性淋巴细胞白血病的初始治疗：一项系统评价和荟萃分析。
Eur J Haematol. 2020 May;104(5):512-515. doi: 10.1111/ejh.13387. Epub 2020 Feb 22.
9
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.低剂量氟达拉滨和环磷酰胺联合标准剂量利妥昔单抗（LD-FCR）治疗老年初治慢性淋巴细胞白血病患者安全有效：以色列 CLL 研究组经验。
Hematol Oncol. 2019 Apr;37(2):185-192. doi: 10.1002/hon.2580. Epub 2019 Mar 12.
10
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.UGT2B17 改变慢性淋巴细胞白血病的药物反应。
Br J Cancer. 2020 Jul;123(2):240-251. doi: 10.1038/s41416-020-0887-6. Epub 2020 May 18.
引用本文的文献
1
Maintenance therapy for chronic lymphocytic leukaemia.慢性淋巴细胞白血病的维持治疗。
Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD013474. doi: 10.1002/14651858.CD013474.pub2.
2
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.BTK 抑制剂在血液系统恶性肿瘤和炎症性疾病治疗中的作用机制及临床研究。
J Hematol Oncol. 2022 Oct 1;15(1):138. doi: 10.1186/s13045-022-01353-w.
3
Targeting Bruton's Tyrosine Kinase in CLL.针对慢性淋巴细胞白血病中的布鲁顿酪氨酸激酶。
Front Immunol. 2021 Jun 23;12:687458. doi: 10.3389/fimmu.2021.687458. eCollection 2021.
本文引用的文献
1
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.接受依鲁替尼治疗的慢性淋巴细胞白血病患者实现完全缓解：临床意义及预测因素
Blood. 2020 Feb 13;135(7):510-513. doi: 10.1182/blood.2019003570.
2
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.伊布替尼联合利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的比较
N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.
3
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.伊布替尼方案与化疗免疫治疗在未经治疗的老年 CLL 患者中的比较。
N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.
4
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.iwCLL 指南：用于 CLL 的诊断、治疗指征、疗效评估和支持性管理。
Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.
5
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.在慢性淋巴细胞白血病中伊布替尼的深度和持久性反应：2 期研究的 5 年随访。
Blood. 2018 May 24;131(21):2357-2366. doi: 10.1182/blood-2017-12-820910. Epub 2018 Feb 26.
Zotero 插件